Researchers at Kanazawa University, Japan, have reported a mixed-glial culture on/in soft substrate (MGS) platform to investigate cancer-glia interactions in vitro. Using this model, they showed that astrocytes favored brain metastasis by promoting metabotropic glutamate mGlu1 receptor (mGluR1) expression in cancer cells and stabilizing EGFR. Eishu Hirata, an associate professor at the Cancer Research Institute, Division of Tumor Cell Biology and Bioimaging at Kanazawa University, and his team
published their work on Feb. 2, 2024, in Developmental Cell. Read More
Aquaporins (AQPs) are membrane proteins distributed over different organs and tissues that facilitate the interchange of water or solutes across membranes. One of these AQPs, named AQP7, has been shown to regulate signaling responses to cellular stress in breast cancer, and is hence considered a therapeutic target in cancer treatment. Read More
At the ongoing WORLDSymposium meeting in San Diego, Gain Therapeutics Inc. presented preclinical data on the company’s GCase enhancer GT-02287 as a potential approach to rescue motor function in Parkinson’s disease (PD). Read More
Aatec Medical GmbH has announced the start of its collaboration with the German Federal Agency for Disruptive Innovations (SPRIND), which will help advance the preclinical development of ATL-105. Read More
A recent Vividion Therapeutics Inc. patent describes Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer. Read More
Aprea Therapeutics Inc. has submitted an IND application to the FDA to initiate clinical trials of APR-1051, an oral next-generation small-molecule inhibitor of WEE1 kinase. Read More
Muna Therapeutics ApS has disclosed new triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes, obesity, metabolic dysfunction-associated steatotic liver disease, neurodegenerative and inflammatory bowel disease, among others. Read More
The Foundation for the National Institutes of Health (FNIH) has announced the online publication of the first playbook designed to help accelerate the development of adeno-associated virus (AAV) gene therapies for rare diseases. Read More
Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and the University of Michigan have prepared and tested new protein cereblon (CRBN) ligands expected to be useful for the treatment of cancer and inflammatory disorders. Read More
Cantabio Pharmaceuticals Inc. has been awarded a grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of a cell-penetrant DJ-1 protein replacement therapeutic candidate for the treatment of Parkinson’s disease. Read More
Humanwell Healthcare (Group) Co. Ltd. has described heterocyclic fused benzene ring compounds acting as dual microtubule destabilizers (tubulin polymerization inhibitors) and proto-oncogene tyrosine-protein kinase Src (SRC; SRC1) inhibitors. Read More
